PittsburghV1, Main, Exploration, bibRecord, 001698

Regorafenib inhibits colorectal tumor growth through PUMA-mediated apoptosis

Identifieur interne : 001698 ( Main/Exploration ); précédent : 001697; suivant : 001699

Regorafenib inhibits colorectal tumor growth through PUMA-mediated apoptosis

Auteurs : Dongshi Chen [États-Unis] ; Liang Wei [États-Unis] ; Jian Yu [États-Unis] ; Lin Zhang [États-Unis]

Source :

Clinical cancer research : an official journal of the American Association for Cancer Research [ 1078-0432 ] ; 2014.

RBID : PMC:4079733

Descripteurs français

English descriptors

KwdEn :
- Animals, Antineoplastic Agents (pharmacology), Apoptosis (drug effects), Apoptosis (genetics), Apoptosis Regulatory Proteins (genetics), Apoptosis Regulatory Proteins (metabolism), Cell Line, Tumor, Colorectal Neoplasms (genetics), Colorectal Neoplasms (pathology), Disease Models, Animal, Drug Resistance, Neoplasm (genetics), Female, Gene Expression Regulation, Neoplastic (drug effects), Glycogen Synthase Kinase 3 (metabolism), Glycogen Synthase Kinase 3 beta, Humans, Mice, NF-kappa B (metabolism), Neovascularization, Pathologic (genetics), Phenylurea Compounds (pharmacology), Promoter Regions, Genetic, Protein Binding, Proto-Oncogene Proteins (genetics), Proto-Oncogene Proteins (metabolism), Pyridines (pharmacology), Transcriptional Activation (drug effects), Up-Regulation, Xenograft Model Antitumor Assays.
MESH :
- chemical , genetics : Apoptosis Regulatory Proteins, Proto-Oncogene Proteins.
- chemical , metabolism : Apoptosis Regulatory Proteins, Glycogen Synthase Kinase 3, NF-kappa B, Proto-Oncogene Proteins.
- chemical , pharmacology : Antineoplastic Agents, Phenylurea Compounds, Pyridines.
- drug effects : Apoptosis, Gene Expression Regulation, Neoplastic, Transcriptional Activation.
- genetics : Apoptosis, Colorectal Neoplasms, Drug Resistance, Neoplasm, Neovascularization, Pathologic.
- pathology : Colorectal Neoplasms.
- Animals, Cell Line, Tumor, Disease Models, Animal, Female, Glycogen Synthase Kinase 3 beta, Humans, Mice, Promoter Regions, Genetic, Protein Binding, Up-Regulation, Xenograft Model Antitumor Assays.

Abstract

Purpose

Regorafenib, a multi-kinase inhibitor targeting the Ras/Raf/MEK/ERK pathway, has recently been approved for the treatment of metastatic colorectal cancer (CRC). However, the mechanisms of action of regorafenib in CRC cells have been unclear. We investigated how regorafenib suppresses CRC cell growth and potentiates effects of other chemotherapeutic drugs.

Experimental Design

We determined whether and how regorafenib induces the expression of PUMA, a p53 target and a critical mediator of apoptosis in CRC cells. We also investigated whether PUMA is necessary for the killing and chemosensitization effects of regorafenib in CRC cells. Furthermore, xenograft tumors were used to test if PUMA mediates the in vivo antitumor, antiangiogenic and chemosensitization effects of regorafenib.

Results

We found that regorafenib treatment induces PUMA in CRC cells irrespective of p53 status through the NF-κB pathway following ERK inhibition and glycogen synthase kinase 3β (GSK3β) activation. Upregulation of PUMA is correlated with apoptosis induction in different CRC cell lines. PUMA is necessary for regorafenib-induced apoptosis in CRC cells. Chemosensitization by regorafenib is mediated by enhanced PUMA induction through different pathways. Furthermore, deficiency in PUMA abrogates the in vivo antitumor, antiangiogenic and chemosensitization effects of regorafenib.

Conclusions

Our results demonstrate a key role of PUMA in mediating the anticancer effects of regorafenib in CRC cells. They suggest that PUMA induction can be used as an indicator of regorafenib sensitivity, and also provide a rationale for manipulating the apoptotic machinery to improve the therapeutic efficacy of regorafenib and other targeted drugs.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4079733

DOI: 10.1158/1078-0432.CCR-13-2944
PubMed: 24763611
PubMed Central: 4079733

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Regorafenib inhibits colorectal tumor growth through PUMA-mediated apoptosis</title>
<author><name sortKey="Chen, Dongshi" sort="Chen, Dongshi" uniqKey="Chen D" first="Dongshi" last="Chen">Dongshi Chen</name>
<affiliation wicri:level="2"><nlm:aff id="A1">University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><nlm:aff id="A2">Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Wei, Liang" sort="Wei, Liang" uniqKey="Wei L" first="Liang" last="Wei">Liang Wei</name>
<affiliation wicri:level="2"><nlm:aff id="A1">University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><nlm:aff id="A3">Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Yu, Jian" sort="Yu, Jian" uniqKey="Yu J" first="Jian" last="Yu">Jian Yu</name>
<affiliation wicri:level="2"><nlm:aff id="A1">University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><nlm:aff id="A3">Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Zhang, Lin" sort="Zhang, Lin" uniqKey="Zhang L" first="Lin" last="Zhang">Lin Zhang</name>
<affiliation wicri:level="2"><nlm:aff id="A1">University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><nlm:aff id="A2">Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">24763611</idno>
<idno type="pmc">4079733</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4079733</idno>
<idno type="RBID">PMC:4079733</idno>
<idno type="doi">10.1158/1078-0432.CCR-13-2944</idno>
<date when="2014">2014</date>
<idno type="wicri:Area/Pmc/Corpus">001910</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001910</idno>
<idno type="wicri:Area/Pmc/Curation">001885</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">001885</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000771</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000771</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="wicri:Area/PubMed/Corpus">002520</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002520</idno>
<idno type="wicri:Area/PubMed/Curation">002510</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002510</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002510</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002510</idno>
<idno type="wicri:Area/Ncbi/Merge">001C87</idno>
<idno type="wicri:Area/Ncbi/Curation">001C87</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001C87</idno>
<idno type="wicri:doubleKey">1078-0432:2014:Chen D:regorafenib:inhibits:colorectal</idno>
<idno type="wicri:Area/Main/Merge">001741</idno>
<idno type="wicri:Area/Main/Curation">001698</idno>
<idno type="wicri:Area/Main/Exploration">001698</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Regorafenib inhibits colorectal tumor growth through PUMA-mediated apoptosis</title>
<author><name sortKey="Chen, Dongshi" sort="Chen, Dongshi" uniqKey="Chen D" first="Dongshi" last="Chen">Dongshi Chen</name>
<affiliation wicri:level="2"><nlm:aff id="A1">University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><nlm:aff id="A2">Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Wei, Liang" sort="Wei, Liang" uniqKey="Wei L" first="Liang" last="Wei">Liang Wei</name>
<affiliation wicri:level="2"><nlm:aff id="A1">University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><nlm:aff id="A3">Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Yu, Jian" sort="Yu, Jian" uniqKey="Yu J" first="Jian" last="Yu">Jian Yu</name>
<affiliation wicri:level="2"><nlm:aff id="A1">University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><nlm:aff id="A3">Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Zhang, Lin" sort="Zhang, Lin" uniqKey="Zhang L" first="Lin" last="Zhang">Lin Zhang</name>
<affiliation wicri:level="2"><nlm:aff id="A1">University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><nlm:aff id="A2">Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Clinical cancer research : an official journal of the American Association for Cancer Research</title>
<idno type="ISSN">1078-0432</idno>
<imprint><date when="2014">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antineoplastic Agents (pharmacology)</term>
<term>Apoptosis (drug effects)</term>
<term>Apoptosis (genetics)</term>
<term>Apoptosis Regulatory Proteins (genetics)</term>
<term>Apoptosis Regulatory Proteins (metabolism)</term>
<term>Cell Line, Tumor</term>
<term>Colorectal Neoplasms (genetics)</term>
<term>Colorectal Neoplasms (pathology)</term>
<term>Disease Models, Animal</term>
<term>Drug Resistance, Neoplasm (genetics)</term>
<term>Female</term>
<term>Gene Expression Regulation, Neoplastic (drug effects)</term>
<term>Glycogen Synthase Kinase 3 (metabolism)</term>
<term>Glycogen Synthase Kinase 3 beta</term>
<term>Humans</term>
<term>Mice</term>
<term>NF-kappa B (metabolism)</term>
<term>Neovascularization, Pathologic (genetics)</term>
<term>Phenylurea Compounds (pharmacology)</term>
<term>Promoter Regions, Genetic</term>
<term>Protein Binding</term>
<term>Proto-Oncogene Proteins (genetics)</term>
<term>Proto-Oncogene Proteins (metabolism)</term>
<term>Pyridines (pharmacology)</term>
<term>Transcriptional Activation (drug effects)</term>
<term>Up-Regulation</term>
<term>Xenograft Model Antitumor Assays</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Activation de la transcription ()</term>
<term>Animaux</term>
<term>Antinéoplasiques (pharmacologie)</term>
<term>Apoptose ()</term>
<term>Apoptose (génétique)</term>
<term>Facteur de transcription NF-kappa B (métabolisme)</term>
<term>Femelle</term>
<term>Glycogen Synthase Kinase 3 (métabolisme)</term>
<term>Glycogen synthase kinase 3 beta</term>
<term>Humains</term>
<term>Liaison aux protéines</term>
<term>Lignée cellulaire tumorale</term>
<term>Modèles animaux de maladie humaine</term>
<term>Néovascularisation pathologique (génétique)</term>
<term>Phénylurées (pharmacologie)</term>
<term>Protéines proto-oncogènes (génétique)</term>
<term>Protéines proto-oncogènes (métabolisme)</term>
<term>Protéines régulatrices de l'apoptose (génétique)</term>
<term>Protéines régulatrices de l'apoptose (métabolisme)</term>
<term>Pyridines (pharmacologie)</term>
<term>Régions promotrices (génétique)</term>
<term>Régulation de l'expression des gènes tumoraux ()</term>
<term>Régulation positive</term>
<term>Résistance aux médicaments antinéoplasiques (génétique)</term>
<term>Souris</term>
<term>Tests d'activité antitumorale sur modèle de xénogreffe</term>
<term>Tumeurs colorectales (anatomopathologie)</term>
<term>Tumeurs colorectales (génétique)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Apoptosis Regulatory Proteins</term>
<term>Proto-Oncogene Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Apoptosis Regulatory Proteins</term>
<term>Glycogen Synthase Kinase 3</term>
<term>NF-kappa B</term>
<term>Proto-Oncogene Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antineoplastic Agents</term>
<term>Phenylurea Compounds</term>
<term>Pyridines</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Tumeurs colorectales</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Apoptosis</term>
<term>Gene Expression Regulation, Neoplastic</term>
<term>Transcriptional Activation</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Apoptosis</term>
<term>Colorectal Neoplasms</term>
<term>Drug Resistance, Neoplasm</term>
<term>Neovascularization, Pathologic</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Apoptose</term>
<term>Néovascularisation pathologique</term>
<term>Protéines proto-oncogènes</term>
<term>Protéines régulatrices de l'apoptose</term>
<term>Résistance aux médicaments antinéoplasiques</term>
<term>Tumeurs colorectales</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Facteur de transcription NF-kappa B</term>
<term>Glycogen Synthase Kinase 3</term>
<term>Protéines proto-oncogènes</term>
<term>Protéines régulatrices de l'apoptose</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Colorectal Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antinéoplasiques</term>
<term>Phénylurées</term>
<term>Pyridines</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Cell Line, Tumor</term>
<term>Disease Models, Animal</term>
<term>Female</term>
<term>Glycogen Synthase Kinase 3 beta</term>
<term>Humans</term>
<term>Mice</term>
<term>Promoter Regions, Genetic</term>
<term>Protein Binding</term>
<term>Up-Regulation</term>
<term>Xenograft Model Antitumor Assays</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Activation de la transcription</term>
<term>Animaux</term>
<term>Apoptose</term>
<term>Femelle</term>
<term>Glycogen synthase kinase 3 beta</term>
<term>Humains</term>
<term>Liaison aux protéines</term>
<term>Lignée cellulaire tumorale</term>
<term>Modèles animaux de maladie humaine</term>
<term>Régions promotrices (génétique)</term>
<term>Régulation de l'expression des gènes tumoraux</term>
<term>Régulation positive</term>
<term>Souris</term>
<term>Tests d'activité antitumorale sur modèle de xénogreffe</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><sec id="S1"><title>Purpose</title>
<p id="P1">Regorafenib, a multi-kinase inhibitor targeting the Ras/Raf/MEK/ERK pathway, has recently been approved for the treatment of metastatic colorectal cancer (CRC). However, the mechanisms of action of regorafenib in CRC cells have been unclear. We investigated how regorafenib suppresses CRC cell growth and potentiates effects of other chemotherapeutic drugs.</p>
</sec>
<sec id="S2"><title>Experimental Design</title>
<p id="P2">We determined whether and how regorafenib induces the expression of PUMA, a p53 target and a critical mediator of apoptosis in CRC cells. We also investigated whether PUMA is necessary for the killing and chemosensitization effects of regorafenib in CRC cells. Furthermore, xenograft tumors were used to test if PUMA mediates the <italic>in vivo</italic>
 antitumor, antiangiogenic and chemosensitization effects of regorafenib.</p>
</sec>
<sec id="S3"><title>Results</title>
<p id="P3">We found that regorafenib treatment induces PUMA in CRC cells irrespective of p53 status through the NF-κB pathway following ERK inhibition and glycogen synthase kinase 3β (GSK3β) activation. Upregulation of PUMA is correlated with apoptosis induction in different CRC cell lines. PUMA is necessary for regorafenib-induced apoptosis in CRC cells. Chemosensitization by regorafenib is mediated by enhanced PUMA induction through different pathways. Furthermore, deficiency in PUMA abrogates the <italic>in vivo</italic>
 antitumor, antiangiogenic and chemosensitization effects of regorafenib.</p>
</sec>
<sec id="S4"><title>Conclusions</title>
<p id="P4">Our results demonstrate a key role of PUMA in mediating the anticancer effects of regorafenib in CRC cells. They suggest that PUMA induction can be used as an indicator of regorafenib sensitivity, and also provide a rationale for manipulating the apoptotic machinery to improve the therapeutic efficacy of regorafenib and other targeted drugs.</p>
</sec>
</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Pennsylvanie</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Pennsylvanie"><name sortKey="Chen, Dongshi" sort="Chen, Dongshi" uniqKey="Chen D" first="Dongshi" last="Chen">Dongshi Chen</name>
</region>
<name sortKey="Chen, Dongshi" sort="Chen, Dongshi" uniqKey="Chen D" first="Dongshi" last="Chen">Dongshi Chen</name>
<name sortKey="Wei, Liang" sort="Wei, Liang" uniqKey="Wei L" first="Liang" last="Wei">Liang Wei</name>
<name sortKey="Wei, Liang" sort="Wei, Liang" uniqKey="Wei L" first="Liang" last="Wei">Liang Wei</name>
<name sortKey="Yu, Jian" sort="Yu, Jian" uniqKey="Yu J" first="Jian" last="Yu">Jian Yu</name>
<name sortKey="Yu, Jian" sort="Yu, Jian" uniqKey="Yu J" first="Jian" last="Yu">Jian Yu</name>
<name sortKey="Zhang, Lin" sort="Zhang, Lin" uniqKey="Zhang L" first="Lin" last="Zhang">Lin Zhang</name>
<name sortKey="Zhang, Lin" sort="Zhang, Lin" uniqKey="Zhang L" first="Lin" last="Zhang">Lin Zhang</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Amérique/explor/PittsburghV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001698 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001698 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Amérique
   |area=    PittsburghV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     PMC:4079733
   |texte=   Regorafenib inhibits colorectal tumor growth through PUMA-mediated apoptosis
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:24763611" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a PittsburghV1

This area was generated with Dilib version V0.6.38.
Data generation: Fri Jun 18 17:37:45 2021. Site generation: Fri Jun 18 18:15:47 2021

Serveur d'exploration sur Pittsburgh

Regorafenib inhibits colorectal tumor growth through PUMA-mediated apoptosis

Regorafenib inhibits colorectal tumor growth through PUMA-mediated apoptosis

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Serveur d'exploration sur Pittsburgh
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.